Bayesian sample sizes for exploratory clinical trials comparing multiple
  experimental treatments with a control by Whitehead, John et al.
1 
 
 
 
 
Bayesian sample sizes for exploratory clinical trials comparing 
multiple experimental treatments with a control 
 
John Whitehead
a
*
+
, Faye Cleary
b
 and Amanda Turner
a 
a
Department of Mathematics and Statistics, Lancaster University, UK  
b
GlaxoSmithKline, Stockley Park, UK 
 
11 July 2014 
 
 
SUMMARY  
 
In this paper, a Bayesian approach is developed for simultaneously comparing multiple 
experimental treatments with a common control treatment in an exploratory clinical trial.  
The sample size is set to ensure that, at the end of the study, there will be at least one 
treatment for which the investigators have a strong belief that it is better than control, or else 
they have a strong belief that none of the experimental treatments are substantially better than 
control.  This criterion bears a direct relationship with conventional frequentist power 
requirements, while allowing prior opinion to feature in the analysis with a consequent 
reduction in sample size.  If it is concluded that at least one of the experimental treatments 
shows promise, then it is envisaged that one or more of these promising treatments will be 
developed further in a definitive phase III trial.   
The approach is developed in the context of normally distributed responses sharing a 
common standard deviation regardless of treatment.  To begin with, the standard deviation 
will be assumed known when the sample size is calculated.  The final analysis will not rely 
upon this assumption, although the intended properties of the design may not be achieved if 
the anticipated standard deviation turns out to be inappropriate.  Methods that formally allow 
for uncertainty about the standard deviation, expressed in the form of a Bayesian prior, are 
then explored. 
 Illustrations of the sample sizes computed from the new method are presented, and 
comparisons are made with frequentist methods devised for the same situation. 
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1.    Introduction 
A commonly occurring situation in clinical research is the need to evaluate simultaneously 
alternative new approaches to the treatment of the same condition.  In the pharmaceutical 
industry, the alternatives might be different doses, formulations or administration schedules 
of the same experimental drug, or they might relate to the use of that drug with and without 
one or more concurrent medications.  In the public sector, a head-to-head comparison of 
several drugs or other forms of treatment from different sources might be of interest.  The 
method described here considers the treatments to be qualitatively different.  For example, if 
they do represent different doses of the same drug, no assumptions are made concerning the 
dose-response relationship, and if they are different combinations of the same set of drugs, no 
interactions are ignored.  A clinical trial is considered in which patients are randomised 
between k new treatments and a control treatment.  The latter might comprise or include 
administration of a placebo, otherwise it will often represent a standard form of treatment.  
Often, multiple treatments are assessed during phase II of a drug development programme, 
with a view to selecting one or more of them for further investigation in phase III.  This paper 
is written in that setting, although the methods presented might be applicable in different 
contexts.  In this paper, the whole trial is completed in a single stage, although the 
methodology would lend itself to a multi-stage approach.  
 Frequentist sample size calculations for multiple treatment comparisons are usually 
based on considerations of type I error and power.  Type I error is the probability of claiming 
that one or more of the experimental treatments is better than control (and therefore worthy of 
further investigation), when in fact all treatments have the same effect.  The power will be the 
probability of reaching the same conclusion under a specific scenario in which one of the new 
treatments is indeed superior to placebo by a specified margin.  An attractive frequentist 
solution to this problem was suggested by Dunnett [1], and this approach has been 
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implemented in trials such as an anti-hypertensive study described by Carlsen et al. [2] (data 
from which are used for an illustration in Section 5 below) and generalised to multi-stage 
trials [3, 4].  Other frequentist sample size calculations for single-stage multiple-treatment 
trials have also been suggested [5, 6].  These are based on a final F-test to determine whether 
a difference between the treatments exists, and are unsuitable when one of the treatments is a 
control and it is important to know which treatments are the most efficacious. 
In this paper, we develop a Bayesian approach to sample size determination for 
multiple treatment trials.  It is an extension of the method described by Whitehead et al. [7], 
extending an approach mentioned by Simon [8], to comparisons of a single experimental 
treatment with control.  Reference [7] includes a review of a range of Bayesian methods that 
have been suggested for setting sample size.  Spiegelhalter et al. [9], classify such approaches 
as “hybrid classical and Bayesian”, “proper Bayesian” and “decision-theoretic Bayesian”.  
The first of these uses Bayesian methodology only for the design of the trial, assuming that 
the final analysis will be frequentist: an example is provided by O’Hagan and Stevens [10].  
Proper Bayesian methods are usually based on the predictive power of a final Bayesian 
analysis.  This paper adopts a slightly different approach which is nevertheless “proper 
Bayesian”.  Finally, another Bayesian option for setting sample sizes is to use decision theory 
[11, 12]. 
 The method of [7] concerns a parameter  representing the advantage of a single 
experimental treatment over the control.  While the value  = 0 represents no difference 
between the treatments, the value  = * (where * > 0) would reflect a clinically important 
treatment effect.  The Bayesian criterion for the required sample size starts with a prior 
distribution for , which will be transformed into a posterior distribution after observing the 
trial data.  If the posterior belief that > 0 is large enough, then it will be concluded that the 
experimental treatment is promising and research will proceed to a definitive phase III trial, 
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while if the posterior belief that < * is large enough, then development of the treatment 
will be abandoned.  The sample size is set to ensure that the posterior belief will satisfy one 
of these conditions, so that an inconclusive study is avoided.  Cases of binary and normally 
distributed responses were considered in [7], and extensions to trials yielding survival data 
are possible [13]. 
 
2. A Bayesian approach to sample size determination 
Suppose that patients are randomised between a control treatment, E0, and k experimental 
treatments, E1, ..., Ek.  The response yij of the i
th
 patient on treatment Ej is distributed 
normally with mean j and precision  (so that the variance = 
1
) for i = 1, ..., nj; j = 0, 1, ..., 
k.  To begin with, we assume that the value of  is known.  Treatment effects are denoted by 
j = j – 0, j = 1, ..., k.  Independent normal priors for j are imposed: 
j ~ N(j, (q0j)
1
),   j = 0, 1, ..., k.   
Denoting the mean response of patients on Ej by jy , these priors lead to independent normal 
posteriors for j:  
j ~ N(j, (q1j)
1
),    
where  
   1j 0 j 0 j j j 0 j jq n y q n         
and q1j = q0j + nj represents the total amount of information, both prior and observed, 
available about patients’ response to treatment Ej,  j = 0, 1, ..., k.  Thus the posterior mean, 
1j, is a weighted average of the prior mean, 0j, and the average of the observed responses on  
Ej, jy .  The joint posterior distribution for (1, ..., k) is therefore multivariate normal: 
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 where  
1j = 1j – 10 and D1j = q1jq10/(q1j + q10),  j = 1, ..., k.   
We assume that the trial is designed to yield equal information concerning each of the 
experimental treatments: that is q11 = ... = q1k, with common value denoted by q1.  Thus, 
sample sizes will be chosen to ensure that q01 + n1 = ... = q0k + nk.  It follows that the D1j will 
be equal to one another, and their common value is denoted by D1.  
 Two criteria for a sufficiently large sample size will be considered.  To express the 
first of these, denote the data collected in the trial by y, and posterior probabilities based on 
these data by P(  y).  Let 
    j j jP 0 and P for all j 1,...,k         y y , 
where * > 0 denotes a treatment effect of clinical importance.  Hence, j is the posterior 
probability that treatment Ej shows promise and  is the posterior probability that none of the 
experimental treatments have a clinically important effect.  The first criterion is as follows. 
Criterion 1:  The sample size should be sufficient to ensure that either j ≥  for at least one 
j = 1, ..., k, or  ≥ , for any possible outcome dataset y.   
If the first of the possibilities guaranteed by Criterion 1 arises, then one or more of the 
treatments Ej for which j ≥  will be developed further; if the second is true, then all of the 
treatments will be abandoned.  The values of  and  will be large, and certainly greater than 
0.5.  There will be a small but positive probability that a dataset with the specified sample 
size will result in both j ≥  for at least one j = 1, ..., k and  ≥  being true.  In such a case, 
at least one treatment is showing promise but none appear to have an important effect.  The 
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sample size is adequate for the decision as to whether to study some treatment further, but 
further considerations such as safety or cost will be needed to reach a conclusion. 
 In order to calculate a suitable sample size before the study is conducted, consider a 
borderline outcome in which the posterior mean value for j is 1j = 1 , j = 1, ..., k, leading to 
1 = ... = k =  and  = .  If 1j > 1  for any j then j >  and further testing of treatment 
Ej will be recommended. If 1j ≤ 1  for all j, with strict inequality for at least one, then  >  
and no further testing of any treatment will be recommended.  This situation is represented 
for a particular case with k = 2 in Figure 1, where the borderline outcome occurs at the single 
point (11, 12) in the space of possible posterior mean treatment effects at which the Abandon 
boundary and the Proceed boundary meet. 
In the case of general k, because    j j 1 11 P 0 D       y , it follows that 
 
1 2
1 1z D


   , j = 1, ..., k, where z = 
1
().  Consider the random vector X  (X1, ..., Xk) 
following a normal distribution with mean 0 and variance-covariance matrix  for which all 
diagonal elements are equal to 1 and all off-diagonal elements are equal to   [0, 1].  Let 
x,,k denote the value such that P(max(X1, ..., Xk) < x,,k) = .  The value of x,,k can easily 
be computed, or found from software such as the R program of Genz et al. [14].  Now, for 
this borderline situation, 
 
  
       
1 k
1 1 1 k 1 1 1 1
P max ,...,
  P max D ,..., D D


     
              
y
y
                                                        
and so  1 1 , ,kD x      with  = (1 + r)1 where r = q10/q1.  The quantity r is the ratio of 
posterior information required about the control treatment to that for the experimental 
treatments, and is set by the investigators.  It follows that   1 21 1 , ,kz D D x        .  
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Therefore, sample sizes n0, n1, ..., nk should be chosen so that so that D11 = ... = D1k = D1 = 
V1/, where V1 = {(z + x,,k)/*}
2
.  This means that we require 
 1 10
1 1 10 00 0 0 j j 1
q q1 1 1
D q q q n q n V
 
   
 
,   j = 1, ..., k.                                                (1) 
It follows that the minimum suitable total sample size is achieved through the choices 
nj = (1 + k
1/2
)V1/ q0j, j = 1, ..., k,   and   n0 = (1 + k
1/2
)V1/ q00,                        (2) 
and that the optimal allocation ratio r for Criterion 1 is r = (n0 + q00)/(nj + q0j) = k
1/2
.  This is 
consistent with the corresponding approximate frequentist result that the optimal allocation of 
patients satisfies n0/nj = k
1/2
 [15, 16].  
To compute the values of j and  at the end of a study, when the q1j may not turn out 
to be equal, notice that 
    j j 1j 1j1 P 0 D       y ,                                .                                          (3) 
and  
 
     
    
1 k
k
10 0 1j 1j 0 10 10 0
j 1
k
1j 10 1j 1j
j 1
P all of ,..., are
  q q q d
  u q q q u du.









     
 
            
 
 
       
 


y
                         (4) 
Alternatively,  can be calculated directly from the joint distribution of 1, ..., k given above, 
using a multivariate normal package such as [14].  In equations (3) and (4), the possibility 
that the D1j and the q1j might not be equal is accommodated, as sample sizes might not turn 
out to be quite the same as specified by the design. 
 A second sample size criterion involves the quantity * defined as 
 
   
j
k
1 10 1j 1
j 1
P 0 for at least one j 1,..., k
     1 u q q q u du,




    
 
      
 

y
                                                    (5) 
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and is expressed as follows. 
Criterion 2:  The sample size should be sufficient to ensure that either * ≥  or that  ≥  
for any possible outcome dataset y.   
If the first of the possibilities guaranteed by Criterion 2 arises, then one or more of the 
treatments Ej will be developed further; if the second is true, then all of the treatments will be 
abandoned.  As for Criterion 1, the values of  and  will be greater than 0.5.   There will be 
a small but positive probability that a dataset with the specified sample size will result in both 
 ≥  and  ≥  being true, in which case further considerations will be needed to decide 
whether to proceed to further clinical study. 
In order to calculate a suitable sample size, consider the limiting form of dataset y in 
which all of the 1j are equal to ∞, except for 1h, * = P(h > 0  y) = (1h√(D1)) and  = 
P(h < *  y) = ((*  1h)√(D1)).  Criterion 2 is then satisfied if √(D1) = (z + z)/*.  To 
achieve this result for all situations in which all but one of the 1j are equal to ∞, we choose 
n0, n1, ..., nk so that D11 = ... = D1k = D1 = V2/, where V2 = {(z + z)/*}
2
.  This means that 
the sample sizes should be chosen to ensure that  
 1 10
1 1 10 00 0 0 j j 2
q q1 1 1
D q q q n q n V
 
   
 
,   j = 1, ..., k.                                                (6) 
Optimal sample sizes will satisfy (2), with V1 replaced by V2.  This limiting case is 
represented for k = 2 in Figure 2, as the asymptotic values of (11, 12) where the Abandon 
boundary and the Proceed boundary meet. 
 For sample sizes as specified by (6), Criterion 2 will be fulfilled in general, as will 
now be explained.  Consider the random vector X  (X1, ..., Xk) following a normal 
distribution, now with mean that can take any value, and with variance-covariance matrix  
for which all diagonal elements are equal to 1 and all off-diagonal elements are equal to   
[0, 1].  It is shown in [17] that if P(X1, ..., Xk < 0)   for some   (0, 1), then P(X1, ..., Xk < 
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z z) >  for all   (, 1).  Suppose that * ≤ .  Then P(1, ..., k < 0) 1 .  The 
result from [17] can be applied to the posterior distribution of  identifying Xj with 
j(D1)
1/2
, j = 1, ..., k.  It follows that P(1, ..., k < (z + z)(D1)
1/2
) >, as   (1 , 1) 
because both  and  are assumed to be greater than 0.5.  Equation (6) and the definition of 
V2 show that *(D1)
1/2
  = z + z, and so it follows that  is greater than or equal to the latter 
probability, so that  > .   
As P(max(X1, ..., Xk) < x) < P(X1 < x), it follows that x,,k > z and consequently V1 
> V2.  If sample sizes are set to ensure that Criterion 1 holds, then Criterion 2 will also be 
satisfied. 
The use of Criterion 2 guarantees only that a positive trial outcome will coincide with 
a strong belief that at least one of the k experimental treatments is superior to control.  It is 
possible that the final dataset will not support a strong belief of superiority for any particular 
one of the k experimental treatments, while at the same time not allowing conviction that 
none of them work.  The use of Criterion 1 avoids such a dilemma, and although it leads to 
larger sample sizes, it is to be preferred for most purposes.  For optimality, the ratio r should 
be set to k
1/2
.  Criterion 2 might be of value if a positive trial outcome would lead to further 
phase III development of all of the experimental treatments Ej for which P(j < *  y) < , 
perhaps concentrating on a longer-term and more definitive endpoint.   
 
3. A numerical example 
Suppose that k = 2 experimental treatments are to be compared with control, and that the 
known precision of the responses to be observed is  = 1.  The prior distribution for the mean 
response of each of the experimental treatments is normal with mean 0.25 and precision = 4.  
The corresponding prior distribution for the control treatment is normal with mean 0 and 
precision 16.  The clinically important difference is set to be * = 0.5.  Thus, it is expected 
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that the experimental treatments will be superior to the control by about half of the interesting 
difference: the prior means will be used in the Bayesian analysis of the trial although they 
play no part in determining the sample size.  Prior knowledge of responses to the control 
treatment is being taken to be more reliable than that for the experimental treatments.   
 We set  = 0.95 and  = 0.90.  The optimal ratio of experimental to control 
information is r = 2
1/2
 = 1.4142, and this choice leads to a correlation between posterior 
treatment effects of  = (1 + r)1 = 0.4142.  The value of x0.4142,0.90,2 is 1.5915.  Hence V1 = 
{(1.6449 + 1.5915)/0.5}
2
 = 41.90.  This leads to optimal sample sizes of n1 = n2 = (1 + 2
1/2
) 
41.90/ 4 = 67.52 and n0 = (1 + 2
1/2
) 41.90/1 16 = 85.15.      These values can be rounded 
up to n1 = n2 = 68 and n0 = 86: a total sample size of 222.  Figure 1 shows the decision  
FIGURE 1 NEAR HERE 
(Although Figure 1 is referred to earlier in the paper, the main account of it is here.) 
boundary for the final analysis.  The value of the vector (11, 12) made up of the posterior 
means for the two treatment effects can be plotted on this diagram.  If the plotted point lies to 
the right of the vertical (green) boundary, then 1 ≥ , and it can be concluded that treatment 
E1 shows promise and further clinical study of it is appropriate.  If the plotted point lies above 
the horizontal (green) boundary, then 2 ≥ , and treatment E2 should be developed further.  
If both of these conditions apply, then investigators will need to choose which treatment to 
investigate, or whether to proceed further with both.  Finally, if the plotted point is below and 
to the left of the curved (red) boundary, then ≥ , and it can be concluded that at neither 
treatment is likely to achieve a clinically relevant effect, and that research into them should 
be abandoned.  The vertical green boundary is situated at  
1 2
1 1z D


   which is equal to 
0.2537 in this case.   The sample sizes have been chosen to ensure that there are no points for 
which for which none of 1 ≥ , 2 ≥ , or ≥  occur.  However, there are points lying 
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between the two boundaries for which either both 1 ≥  and ≥ or2 ≥  and ≥  
occur.  If (11, 12) lies in these regions, then further considerations about the treatments will 
have to be used to decide whether to take this line of clinical research further. 
Criterion 2 depends on the value V2 = {(1.645 + 1.282)/}
2
 = 34.26.  From 
expression (5), optimal sample sizes are n1 = n2 = (1 + 2
1/2
)  34.26 and n0 = (1 
+ 2
1/2
)  34.26 .  Practical sample sizes are n0 = 67 and n1 = n2 = 55, totalling 
177.  Figure 2 shows the corresponding decision boundary.  The sample size that follows  
FIGURE 2 NEAR HERE 
(Although Figure 2 is referred to earlier in the paper, the main account of it is here.) 
from Criterion 2 is smaller than that for Criterion 1, although as discussed earlier, this 
reduction in sample size comes at the cost of a risk of indecision concerning the choice of 
which treatment to take forward.  In this context, the Bayesian procedure based on Criterion 1 
does make an adjustment for the testing of multiple treatments. 
For each criterion, the design recommendations involve the collection of more data on 
the control treatment than on each of the experimental treatments, as the control features in 
the estimation both treatment effects.  However, the fact that more prior information is 
available concerning the control reduces the imbalance of randomisation.  Consider Criterion 
1 again, with q01 = q02 = 4 as before.  Suppose that there is so much prior experience with the 
control that q00 = 102.  Then the optimal samples sizes will be n1 = n2 = 68 and no 
observations on control (n0 = 0), leading to a total sample size of 136.  This situation would 
arise if the prior standard deviation for 0 was 0.099, whereas those for 1 and 2 were 0.50.  
Being so much better informed about response to a standard form of treatment, relative to the 
uncertainty about a completely new drug would appear to be quite possible. 
The need to achieve integer sample sizes has introduced approximation into the 
sample size calculations above, with “ideal” but non-integer solutions being rounded up for 
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practical use.  Occasionally, an exhaustive integer search might lead to a smaller total sample 
size than follows from rounding up an optimal solution.  For example, consider again the case 
of Criterion 1, for which we have found a suitable design with (n0, n1, n2) = (86, 68, 68), and 
a total sample size equal to 222.  In fact, five sample size combinations satisfy Criterion 1 
with a total sample size equal to 221.  These are (n0, n1, n2) = (85, 68, 68), (81, 70, 70), (83, 
69, 69), (87, 67, 67) and (89, 66, 66).  However, it is not possible to obtain a suitable design 
with a total sample size less than the smallest integer exceeding (1+k
1/2
)
2
V1/  (q00  + q01  + 
... + q0k), which is  the sum of the unrounded sample sizes given by (2).   
Comparisons with frequentist approaches can be made.  Suppose that the trial is 
considered as two separate comparisons, one of E1 with E0, and the other of E2 with E0.  For j 
= 1 and j = 2, it will be concluded that Ej is worthy of further research if Ej is found to be 
significantly superior to E0 at the 5% significance level (one-sided).  We desire a power of 
90% of drawing such a conclusion if j = 0.5.  If the optimal allocation of m patients to each 
experimental treatment and m0 = m√2 to the control is made, then the information available 
for each pairwise comparison will be m0m/(m0 + m) = m/(1 + 2
1/2
) = 0.586m.  This has to be 
set equal to {(z0.975 + z0.90)/*}
2
 = 34.27.  Hence, m = 58.50 and m0 = 82.74, which would be 
rounded up to m = 59 and m0 = 83 (a total sample size of 201).  Notice that expression (6) 
gives precisely this solution for the Bayesian case based on Criterion 2 when there is no prior 
information on any of the treatments (q00 = q01 = q02 = 0).  The frequentist approach here 
makes no adjustment for multiplicity. 
 Dunnett’s (1984) procedure [1] does make allowance for multiplicity.  The frequentist 
power requirements of Dunnett’s method in the setting of this section can be specified as 
follows.  If 1 = 2 = 0, then the probability of proceeding to further research with either 
experimental treatment should be limited to 0.05.  If 1 = 0.5 and 2 = 0, then the probability 
of proceeding to further research with E1 should be 0.90 (with a corresponding requirement in 
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the case 1 = 0 and 2 = 0.5).  For an optimal sample size, with √2 times as many patients on 
the experimental as on the controls, we need n0 = 100 and n1 = n2 = 71, a total sample size of 
242.  These sample sizes are very close to the values of (n0 + q00) = 101 and (n1 + q10) = 72 
that follow from Criterion 1.  Even greater sample sizes result from the more general form of 
Dunnett’s procedure in which the probability of proceeding to further research with E1 should 
be 0.90 if 1 = 0.5 and 2 is equal to some non-interesting treatment effect lying between 0 
and 0.5.  
 
4. Allowing for uncertainty concerning the precision of patient responses 
So far in this paper, it has been assumed that the precision  of patient responses is known.  
In practice this will not be true.  In frequentist sample size calculations, a specific value has 
to be assumed, in a “what if” style of argument.  If the assumed value turns out to be wrong, 
then the intended power might not be achieved.  Strategies such as sample size reviews [18, 
19, 20] can be employed to reduce the risk of losing power.  The Bayesian approach, on the 
other hand, lends itself to making proper allowance for uncertainty about the value of .   
 Specification of prior opinion about , in the form of a prior distribution, can be 
incorporated within the model.  In particular, take this to be a conjugate gamma distribution, 
parameters 0 and 0 leading to a posterior gamma distribution for  with parameters 1 and 
1.  The latter are given by 1 =0 + 
1
2
n, where n denotes the total sample size and 1 =0 + 
1
2
H, where  
 
jnk
2 2 2
j 0 j 0 j 1j 1j j ij
j 0 i 1
H U q q and U y , j 0,1,...,k
 
        .                                       (7)  
This is consistent with equation (6) of [7].  At the end of a study, regardless of how the 
sample size was determined, the values of j, * and  can be found by integrating the 
forms (1), (2) and (4) multiplied by the posterior gamma density, over .  The final Bayesian 
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decision can be made allowing for uncertainty about the value of .  However, if the sample 
sizes indicated in Section 2 for meeting Criterion 1 are used, it may now be possible to 
observe a dataset such that neither j ≥  for any j = 1, ..., k, nor ≥ , and correspondingly 
for Criterion 2.  In this section, methods will be described for determining sample sizes that 
will satisfy the chosen criterion with high probability, rather than with certainty. 
 As in the known variance case, the posterior distribution of (j 1j)√(D1j), given , 
is standard normal, j = 1, ..., k. Following Appendices 2-4 of [7], it can be seen that J1 = 21 
has a posterior chi-squared distribution with 21 degrees of freedom, independent of the latter 
distribution.  Combining these two results it follows that, if Tj is defined by 
 
 
 j 1j 1 1 1j j 1j
11 1
D D
T
J 2
   
   

,                                                                      (8) 
then Tj follows a t-distribution with 21 degrees-of-freedom.  The Tj have pairwise 
correlations equal to , and it can be shown that 
   
 
   
k
1
1 k
0
t v 2 u
P max T ,...,T t u g v dudv
1
 

     
     
    
  ,                (9) 
where  and  respectively denote the distribution and density functions of a standard normal 
distribution, and g denotes the gamma density with parameters 1 and 
1
2
.  Let tk(21, , ) 
denote the value such that P(max(T1, ..., Tk) ≤ tk(21, , )) = . 
To find a sample size satisfying Criterion 1, we again consider a borderline outcome 
in which the posterior mean value for j takes the common value 1j = 1 , j = 1, ..., k, chosen 
so that 1 = ... = k =  and  = .  From (8) it follows that 
     j j j 1 1 1 1 j 1 1 1 1P 0 P T D P T D                y y y . 
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Hence   
1 2
1 1 1 1 1t 2 , D

      , j = 1, ..., k, where t(s, ) denotes the  point on the t 
distribution function with s degrees-of-freedom.  We also require  ≥ , where for the 
borderline outcome under consideration, 
  
   
1 k
1 1
1 k 1
1
P max ,...,
D
  P max T ,...,T .


     
 
    
  
y
y
 
Thus, we require     1 21 1 1 1 k 1D t 2 , ,         , with D1 given by  
   
2
1 k 11
1
1
t 2 , t 2 , ,
D

      
  
  
.                                                                        (10) 
As 1 is not known until the data have been observed, inequality (10) cannot be used directly 
as the basis of a sample size calculation.  Instead, we will seek a sample size such that the 
probability that (10) is true exceeds some set large value .    
From equation (7), 1 =0 + 
1
2
H.  Following Appendix 4 of [7], it can be seen that K 
= H has a chi-squared distribution with n degrees of freedom.  The prior distribution of J0 = 
20 is chi-squared with 20 degrees of freedom and independent of that of K, so that 
   0 0F K n J 2   follows the F-distribution with n and 20 degrees of freedom and B = 
nF/(20 + nF) the beta distribution with parameters 
1
2
n and 0.  As 1 = 0/(1 – B), 1 will be 
less than or equal to   10 021 Beta n, ,     with probability , where Beta(a, b, ) denotes 
the 100% point on the distribution function of a beta random variable with parameters a and 
b.  Thus, if sample sizes are chosen so that 
 
   
2
1 k 10
1 1
1 02
t 2 , t 2 , ,1
D
1 Beta n, , 
          
   
       
,                                      (11) 
then Criterion 1 will be satisfied with probability ≥ .   
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 Denoting the right-hand side of (11) by Vn, the minimum suitable total sample size n 
satisfies 
  
k
2
1 2
n 0 j
j 0
n 1 k V q

   ,                                                                                          (12) 
with individual treatment sample sizes given by nj = (1 + k
1/2
)Vn q0j, j = 1, ..., k, and n0 = 
(1 + k
1/2
)Vn q00.  This is the same as expression (2) with V1/ replaced by Vn.  A search 
over values of n, or application of an equation solver to (12), will lead to the minimum value 
of n satisfying inequality (11) with the optimal allocation, r = (n0 + q00)/(nj + q0j) = k
1/2
,
 
of 
patients to treatment.  To find the smallest possible sample size, the equation is first solved 
for non-integer values of n, leading non-integer values for n0 and the nj: these are then 
rounded up to integer values and the final integer value of n deduced.  Values of tk(21, , ) 
can be found from the R program of Genz et al. [14], or else (11) can be recast as 
       1 1 1k 1 0 12
0
D
t 2 , , 1 Beta n, , t 2 ,

          

.                                        (13) 
The right-hand side of (13) then can be evaluated for various total sample sizes, allocated 
optimally, and substituted for t in equation (9) to find the smallest n for which the result is not 
less than .  Both approaches were used to find and check the calculations in Section 5 below 
(using SAS to implement the latter method). 
Following similar arguments as led to (11), it follows that suitable sample sizes to 
ensure that Criterion 2 is satisfied with probability ≥  should be chosen to ensure that 
 
   
2
1 10
1 1
1 02
t 2 , t 2 ,1
D
1 Beta n, , *
        
   
       
.                                          (14)     
This expression is easier to use directly than (11), as quantiles of the univariate t-distribution 
are widely available in statistical software. 
 
5. A case study 
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Carlsen et al. [2] describe a clinical trial comparing four doses of bendrofluazide and placebo 
administered to patients suffering from arterial hypertension.   The principal endpoint was the 
mean reduction in systolic blood pressure ( bp) over 10-12 weeks treatment (mm Hg).  The 
results of the trial of bendrofluazide are given in Table I, together with some derived 
statistics.  All four doses were successful in reducing blood pressure, with the top dose 
having the greatest effect.   
TABLE I NEAR HERE 
The authors report that sample sizes of 50 in each of the five treatments groups were 
found following the method of Dunnett [1].  The frequentist power requirements used in [2] 
were as follows.  If 1 = ... = 4 = 0, then the probability of proceeding to further research 
with any of the experimental treatments should be limited to 0.05.  If 1 = 5 and 2 = 3 = 4 = 
0, then the probability of proceeding to further research with E1 should be 0.90 (with 
corresponding requirements should any of the other treatments show such an advantage).  It 
was assumed that the standard deviation of the reduction in blood pressure measurements () 
was equal to 7 mm Hg.  The precise result from Dunnett’s method, with all five sample sizes 
constrained to be equal, is to use a sample size of 47 for each group, a total sample size of 
235.  These sample sizes are recorded in Table II, together with those from the alternative 
designs that are discussed in this section.   
TABLE II NEAR HERE 
According to the Dunnett design based on sample sizes of 47 patients, if Ej* is the 
treatment associated with the highest mean endpoint, then it should be taken forward for 
further study if Zj*  c, where c = 2.16 and 
       j 0 j 0 j j 0 j 0Z 1 n n n n y y 0.693 y y      ,   j = 1, ..., 4.                        (15) 
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Treatment T4 is associated with the highest mean endpoint, so that Zj* = Z4 = 10.29.  As this 
exceeds c = 2.16, the fourth dose (10.0 mg/day) should be selected for further study.  
However, the sample sizes all exceed 47, and they differ from one another.  Furthermore, the 
standard deviation of the observations substantially exceeds the anticipated value of 7.  In 
Table I, the value of Zj is computed for each dose group, where Zj is defined in the same 
way as Zj, but with the actual pooled estimate of standard deviation (based on the treatment 
group in question and the placebo group) used in place of , and the true sample sizes in 
place of those planned at the design stage.  It follows that Zj* = Z4 = 5.21.  Although there is 
no mention in [1] of how a p-value can be computed at the end of a trial, the value given by 
 p = P(Zj* ≥ 5.21  1 = 2 = 3 = 4 = 0). 
is consistent with the approach.  Denoting the observed value of Zj* by z* and the estimate of 
 from the responses on treatment Ej by j, it can be shown that,  
  
k
j j j 0 j0i
j 1 i j i j 0 j 0 j
n nnn
p u u z u du
n n n



 
        
                  
  . 
For these data, p = 0.000000184.  Notice that this approach updates the values of the standard 
deviations by estimation from the data, but they are still treated as fixed.  No allowance is 
made for their estimation from the data.  
Now consider the Bayesian sample size calculation for this case.  Suppose that  = 
1/7
2
 = 0.0204, and that prior information on the four doses indicates that 0 = 0 and 1 = 2 = 
3 = 4 = 9, and q00 = 10 and q01 = q02 = q03 = q04 = 2 (as shown in Table I).  Take  = 0.95 
and  = 0.90.  Following [2], the clinically important difference is set at * = 5.  The optimal 
ratio of control to experimental information is r = 4
1/2
 = 2, and this choice leads to a 
correlation between posterior treatment effects of  = (1 + 2)1 = 0.3333.  The value of 
x0.3333,0.90,4 is 1.8886.  Hence V1 = {(1.6449 + 1.8886)/5}
2
 = 0.4994.  This leads to optimal 
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sample sizes on the experimental treatments of (1 + 4
1/2
) 0.4994/0.0204 2 = 34.71 and n0 = 
(1 + 4
1/2
) 0.4994/0.0204 10 = 63.41.      To a good approximation, a total of 204 patients 
could be recruited, with 35 patients allocated to each of the experimental treatments and 64 to 
control.  In a similar way, suitable sample sizes satisfying Criterion 2 can be found to be 24 
patients on each of the active treatments and 41 on the control: a total of 137.   
Following collection of the data in Table I, a variety of Bayesian analyses can be 
conducted.  Assuming that the common standard deviation really is equal to 7, equations (3) 
and (4) result in the values  = ... =4 = 1 and  = 0 respectively.  The value of *, used 
with Criterion 2, is also 1.  To provide values for numerical checking of computations, we 
also evaluate    10 jP 10 for j 1,...,4     y  and    
15
jP 15 for j 1,...,4     y , to 
obtain (10) = 0.000253 and (15) = 0.689.  This would amount to overwhelming evidence that 
each of the treatment effects is greater than 0, but scepticism as to whether any of them are 
greater than 15. 
 Next, recognising that each treatment group has a different standard deviation, the 
estimated “sd  bp” from Table I is used to find a separate estimate for the precision j of 
each treatment Ej, j = 0, ..., 5.  In equation (3), the argument of  becomes 
    1j 10 0 1j j 10 0 1j jq q q q      , in the last part of equation (4), the argument of  
becomes       1j j 10 0 1j 1j ju q q q      , and similar changes are made to the 
expression for *.    We still obtain  = ... =4 = 1, * = 1 and  = 0 to four decimal 
places, but now (10) = 0.0168 and (15) = 0.562. 
 Now suppose that the uncertainty in the prediction of was anticipated.  The prior 
mean of is taken to be 72 = 0.0204, consistently with the value of common standard 
deviation used in [2].  The largest observed value of standard deviation is 15, corresponding 
20 
 
to a precision of 0.00444.  Choosing a gamma prior for  with parameters 0 = 1 and 0 = 49, 
provides a prior mean value of 0.0204 with a prior probability that   0.00444 of 0.196.  
With hindsight, this would appear to be a sensibly vague choice.  Using the expressions in (7) 
reveals that the posterior distribution of  is gamma with parameters 1 = 1 + 257/2 = 129.5 
and 1 = 49 + 
1
2
H, where H = 46413.54 so that 1 = 23255.77.  The treatment group 
contributions to H are listed in Table I as hj.  To compute the hj, the sums of squares of 
endpoints within each treatment group are needed: these are displayed in Table I as ss.  They 
are deduced from the values of standard errors which are reported in [2] to only one decimal 
place.  Consequently the sums of squares have been reproduced only approximately.  The 
posterior mean of  is 0.00557, corresponding to an estimated standard deviation for the 
observations of  bp of 13.40.  The posterior probability that   0.00444 is 0.00729, 
indicating that there is little uncertainty remaining in the posterior opinion about .  Expected 
values of expressions (3) and (4) can be found, treating them as functions of , and using its 
posterior gamma density.  The resulting values are  = ... =4 = 1, * = 1 and  = 0 to four 
decimal places.  It also follows that (10) = 0.0197 and (15) = 0.563.  In this case, the posterior 
opinion about  is so accurate that allowing for uncertainty makes little difference.  A more 
important distinction between these calculations and the previous set is that these assume a 
common value of  across treatment groups, with uncertainty about its value, whereas the 
earlier calculations took different values of  for each treatment comparison, but neglected 
any uncertainty about their values. 
 The highest dose, 10 mg/day, is associated with the largest mean response, and so it 
should be the one to be taken forward for further research.  The posterior probability that 
each of the other doses actually has a larger mean effect than the top dose can be found, with 
the individual estimated treatment group precisions being used as the j, but without 
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allowance for the uncertainty of the precision: for the sample size collected this appears to be 
unnecessary.  For doses 1.25, 2.5 and 5, the probabilities that the corresponding treatment 
effect is larger than that of 10 mg/day are 0.073, 0.158 and 0.112 respectively.  Unless there 
are safety concerns or cost considerations, the focus of further research should be on the top 
dose.  If there are such concerns, indicating that the top dose should be avoided, then 
Criterion 1 indicates which treatments could be admitted to further research.  In this example, 
as each of 2, 3 and 4 > 0.95 (in fact they are all equal to 1), any of 2, 3 and 4 could be 
developed further. 
 TABLE III NEAR HERE 
Finally, suppose that the uncertainty in the prediction of were allowed for in the 
sample size calculation.  As discussed above, a gamma prior for  with parameters 0 = 1 and 
0 = 49, is adopted.  Setting  = 0.95 and choosing Criterion 1 leads to the optimal sample 
sizes of 714 on each experimental treatment and n0 = 1422 on control: a total of n = 4278 
patients.  There is a very high price to pay for certainty of reaching a convincing conclusion 
in the face of uncertainty about the variability of patient responses.  Because of the mismatch 
between the anticipated standard deviation of the mean reduction in systolic blood pressure 
measurements of 7, and the observed values the largest of which is 15, a broad prior 
distribution was set for .  In Table III, sample sizes for values of  less than the stringent 
setting of 0.95, and for tighter prior distributions for  are presented, for both criteria.  Bear in 
mind that the actual study recruited 257 patients, and so all but one of the designs shown 
would have called for additional subjects.   
 
6. Discussion 
Bayesian methods of design and analysis are attractive for early phase clinical trials in which 
the objective is to decide whether and in what form to take a treatment forward for further 
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clinical research, rather than to reach a definitive conclusion on efficacy.  Bayesian methods 
for sample size calculation complement such analyses, and this paper demonstrates that it is 
relatively easy to extend such calculations to the multiple treatment setting.  Caution about 
using the approach of this paper was expressed by Zaslavsky [21] and discussed by Zaslavsky 
and Whitehead [22] in the context of comparisons between a single experimental treatment 
and a control.  In the multiple treatment setting, even more care is needed in making 
comparisons between sample sizes calculated from frequentist and Bayesian approaches.  
This is because the criteria that each is set to satisfy are so different.  In particular, the 
Bayesian approaches allow for prior opinion effectively to stand in for real prospective 
observations.  These concerns should be less acute during the early phase of drug 
development: the Bayesian approach would appear to be less suited for either the design or 
the analysis of phase III confirmatory studies. 
 Whitehead et al. [7] included discussion of Bayesian sample determination when 
comparing a single experimental treatment with control in terms of non-normally distributed 
endpoints such as binary or ordinal responses.  It was supposed that the advantage of the 
experimental treatment over the control was expressed in terms of the single scalar parameter 
, and that the analysis was to be conducted in terms of the efficient score Z and Fisher’s 
information V.  Approximately, when the amount of information is large and the value of  is 
small, Z is normally distributed with mean V and variance V.  In the Bayesian context, a 
convenient conjugate prior for  is normal with mean Z0/V0 and variance 1/V0, leading to a 
posterior that is normal with mean (Z0 + Z)/(V0 + V) and variance 1/(V0 + V).  When there 
are multiple experimental treatments, E1, ..., Ek, then the advantage of Ej over control can be 
parameterised as j, and the corresponding efficient score statistic and Fisher’s information 
denoted by Zj and Vj respectively, j = 1, ..., k.  The statistics Zh and Zj will be correlated, h, j 
= 1, ..., k, and a form for their covariance can be deduced in each special case (see [23] for 
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the cases of binary and ordinal data).  Using such results and starting with independent priors 
for the j, the method of this paper can be adapted for large trials with non-normal responses.   
 In this paper, two different criteria for specifying a suitable sample size have been 
suggested.  Criterion 1 is likely to be appropriate for most purposes as it ensures that, 
provided the final evidence does not lead to strong evidence that none of the new treatments 
is superior to control, there will be at least one treatment which is strongly supported by the 
evidence.  Criterion 2 may be of use in circumstances where it is not necessary to identify a 
clearly winning treatment before concluding that a longer-term definitive trial is justified.  It 
is interesting to observe that Criterion 1 does adjust the sample size required for the 
multiplicity of experimental treatments, even in a Bayesian context.   
Due to the Bayesian paradigm, no adjustment is required for taking multiple looks at 
data emerging from the trial.  Thus, interim analyses can be performed to assess whether the 
criterion  ≥  is yet satisfied, and if so to stop the study for futility.  The criteria  ≥  , ..., 
k ≥  can also be checked to see whether a winning treatment can be identified early, or if 
Criterion 2 is being used a further trial can be initiated as soon as it is found that * ≥ .  In 
fact, achievement of Criterion 2 could be used as the trigger for investing in the often lengthy 
preparations for a phase III trial, while the current study continues until Criterion 1 is 
satisfied and a winning treatment identified for that subsequent trial.  Appropriate criteria for 
dropping individual experimental treatments early could also be set.  No alteration to the 
maximum sample sizes per treatment will be needed in order to maintain the Bayesian 
properties of the overall procedure.  
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Table I: Data from the study of Carlsen et al., with associated statistics  
and Bayesian quantities   
 
Dose (mg/day) 0 1.25 2.5 5.0 10.0 
n 52 50 52 52 51 
mean  bp 2.8 12.7 14.3 13.4 17.0 
se  bp 1.7 2.0 1.6 2.0 2.1 
sd  bp 12.3 14.1 11.5 14.4 15.0 
ss 8072 17865 17423    19945    25985    
pooled S - 13.2 11.9 13.4 13.7 
Zj - 7.14 8.38 7.72 10.29 
Zj - 3.78 4.93 4.04 5.27 
      
q0j 10 2 2 2 2 
0j 0     9     9     9     9     
q1j 62 52 54 54 53 
1j 2.35     12.56     14.10     13.24     16.70     
1j - 10.21 11.76 10.89 14.35 
hj 7730 9826     6843   10645   11369   
 
 
Table II: Frequentist and Bayesian designs for the case of known precision  = 0.0204 
Frequentist settings: type I error = 0.05; power = 0.90; * = 5 
Bayesian settings: q00 = 10; q01 = q02 = q03 = q04 = 2;  = 0.95;  = 0.90; * = 5 and r = 2 
 
Design type sample size: 
on 
experimental 
treatments 
on control 
treatment 
total 
Trial conducted by Carlsen et al [2] 50-52 50 257 
Frequentist Dunnett design with equal sample sizes 47 47 235 
Bayesian design, Criterion 1 35 64 204 
Bayesian design, Criterion 2 24 41 137 
 
 
Table III: Bayesian designs for the case of unknown precision 
Settings are q00 = 10; q01 = q02 = q03 = q04 = 2;  = 0.95;  = 0.90; * = 5 and r = 2 
 
0 0 prior:  sample size (Criterion 1/Criterion 2): 
expectation 
of  
probability 
that sd ≥ 15 
on experimental 
treatments 
on control 
treatment 
total 
1 49 0.0204 0.196 0.95 714/489 1422/972 4278/2928 
    0.80 163/111 320/216 972/660 
    0.50 52/35 97/63 305/203 
2 98 0.0204 0.071 0.95 205/140 403/274 1223/834 
    0.80 88/59 169/112 521/348 
3 147 0.0204 0.029 0.95 133/91 259/175 791/539 
    0.80 70/48 134/89 414/281 
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Figure 1: An illustrative outcome space based on Criterion 1.  The decision regions are: 
proceed to further research if (11, 12) lies above or to the right of the inner “Proceed 
boundary”; abandon these experimental treatments if (11, 12) lies below and to the left of 
the outer “Abandon boundary”. 
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Figure 2: An illustrative outcome space based on Criterion 2.  The decision regions are: 
proceed to further research if (11, 12) lies above or to the right of the inner “Proceed 
boundary”; abandon these experimental treatments if (11, 12) lies below and to the left of 
the outer “Abandon boundary”. 
 
 
 
